174 related articles for article (PubMed ID: 26093083)
1. Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target.
Zeidan B; Jackson TR; Larkin SE; Cutress RI; Coulton GR; Ashton-Key M; Murray N; Packham G; Gorgoulis V; Garbis SD; Townsend PA
Oncotarget; 2015 Aug; 6(25):21421-7. PubMed ID: 26093083
[TBL] [Abstract][Full Text] [Related]
2. Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance.
Zeng C; Ke Z; Song Y; Yao Y; Hu X; Zhang M; Li H; Yin J
Exp Mol Pathol; 2013 Aug; 95(1):23-31. PubMed ID: 23631820
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Suppressing Effect of Silencing of Annexin A3 Expression in Breast Cancer.
Kim JY; Jung EJ; Park HJ; Lee JH; Song EJ; Kwag SJ; Park JH; Park T; Jeong SH; Jeong CY; Ju YT; Lee YJ; Hong SC
Clin Breast Cancer; 2018 Aug; 18(4):e713-e719. PubMed ID: 29217453
[TBL] [Abstract][Full Text] [Related]
4. Annexin A3 may play an important role in ochratoxin-induced malignant transformation of human gastric epithelium cells.
Wang J; Jia X; Meng X; Li Y; Wu W; Zhang X; Xu H; Cui J
Toxicol Lett; 2019 Oct; 313():150-158. PubMed ID: 31276768
[TBL] [Abstract][Full Text] [Related]
5. Expression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcome.
Zimmermann U; Woenckhaus C; Teller S; Venz S; Langheinrich M; Protzel C; Maile S; Junker H; Giebel J
Histol Histopathol; 2007 May; 22(5):527-34. PubMed ID: 17330807
[TBL] [Abstract][Full Text] [Related]
6. Identification of annexin II as a novel secretory biomarker for breast cancer.
Jeon YR; Kim SY; Lee EJ; Kim YN; Noh DY; Park SY; Moon A
Proteomics; 2013 Nov; 13(21):3145-56. PubMed ID: 24019232
[TBL] [Abstract][Full Text] [Related]
7. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.
Ou K; Yu K; Kesuma D; Hooi M; Huang N; Chen W; Lee SY; Goh XP; Tan LK; Liu J; Soon SY; Bin Abdul Rashid S; Putti TC; Jikuya H; Ichikawa T; Nishimura O; Salto-Tellez M; Tan P
J Proteome Res; 2008 Apr; 7(4):1518-28. PubMed ID: 18318472
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma.
Liu YF; Xiao ZQ; Li MX; Li MY; Zhang PF; Li C; Li F; Chen YH; Yi H; Yao HX; Chen ZC
J Pathol; 2009 Jan; 217(1):54-64. PubMed ID: 18798225
[TBL] [Abstract][Full Text] [Related]
9. Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers.
Korwar AM; Bhonsle HS; Ghole VS; Gawai KR; Koppikar CB; Kulkarni MJ
OMICS; 2013 Jan; 17(1):27-40. PubMed ID: 23301641
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer.
Du R; Liu B; Zhou L; Wang D; He X; Xu X; Zhang L; Niu C; Liu S
Cell Death Dis; 2018 Jan; 9(2):126. PubMed ID: 29374148
[TBL] [Abstract][Full Text] [Related]
11. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
12. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.
Yin J; Yan X; Yao X; Zhang Y; Shan Y; Mao N; Yang Y; Pan L
J Cell Mol Med; 2012 Feb; 16(2):337-48. PubMed ID: 21435174
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of protein patterns of human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines.
Flodrova D; Toporova L; Macejova D; Lastovickova M; Brtko J; Bobalova J
Gen Physiol Biophys; 2016 Jul; 35(3):387-92. PubMed ID: 27174898
[TBL] [Abstract][Full Text] [Related]
14. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
15. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.
Hu X; Zhang Y; Zhang A; Li Y; Zhu Z; Shao Z; Zeng R; Xu LX
OMICS; 2009 Aug; 13(4):291-300. PubMed ID: 19624269
[TBL] [Abstract][Full Text] [Related]
16. Matrix-assisted laser desorption/ionization mass spectrometry imaging of cell cultures for the lipidomic analysis of potential lipid markers in human breast cancer invasion.
Wang S; Chen X; Luan H; Gao D; Lin S; Cai Z; Liu J; Liu H; Jiang Y
Rapid Commun Mass Spectrom; 2016 Feb; 30(4):533-42. PubMed ID: 26777684
[TBL] [Abstract][Full Text] [Related]
17. The HCCR oncoprotein as a biomarker for human breast cancer.
Jung SS; Park HS; Lee IJ; Namkoong H; Shin SM; Cho GW; Ha SA; Park YG; Lee YS; Ko J; Kim JW
Clin Cancer Res; 2005 Nov; 11(21):7700-8. PubMed ID: 16278390
[TBL] [Abstract][Full Text] [Related]
18. Multiple changes induced by fibroblasts on breast cancer cells.
Cancemi P; Albanese NN; DiCara G; Marabeti MR; Costantini F; Minafra S; Pucci-Minafra I
Connect Tissue Res; 2010 Apr; 51(2):88-104. PubMed ID: 20001846
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model.
Kreunin P; Yoo C; Urquidi V; Lubman DM; Goodison S
Proteomics; 2007 Jan; 7(2):299-312. PubMed ID: 17205601
[TBL] [Abstract][Full Text] [Related]
20. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
